Home / Health / MSN Labs Launches Affordable Semaglutide in India
MSN Labs Launches Affordable Semaglutide in India
17 Apr
Summary
- MSN Laboratories launched generic semaglutide as Semabest.
- The new drug is priced nearly 50% lower than the original.
- Semabest is administered via a pre-filled pen for subcutaneous injection.
MSN Laboratories has launched Semabest, its generic version of semaglutide, in India following approval from the Central Drugs Standard Control Organisation (CDSCO). This introduction aims to make the medication more accessible to patients by reducing costs.
The generic Semabest is priced approximately 50% lower than the original innovator drug. It is conveniently supplied in a pre-filled pen for subcutaneous injection, simplifying the administration process for individuals requiring treatment.
Disclaimer: This story has been auto-aggregated and auto-summarised by a computer program. This story has not been edited or created by the Feedzop team.
